65 results on '"Kravchun N"'
Search Results
2. EFFICACY OF FOOD ANTIOXIDANTS AND THERAPEUTIC E XERCISE IN PATIENTS WITH T YPE 2 DIABETES MELLITUS WITH NONALCOHOLIC FATTY LIVER DISEASE
3. PLACE OF MAGNESIUM OROTATE IN THE COMPLEX THERAPY OF PATIENTS WITH TYPE 2 DIABETES MELLITUS WITH HYPERURICEMIA
4. STATUS OF ENDOCRINOLOGICAL SCIENCE AND PROSPECTS FOR ITS DE VELOPMENT IN STATE INSTITUTION «V. DANILE VSK Y INSTITUTE FOR ENDOCRINE PATHOLOGY PROBLEMS OF THE NAMS OF UKRANE» (to the 100th anniversary of its foundation)
5. THE RELATIONSHIP BETWEEN BLOOD LIPID PROFILE AND URICEMIA LEVELS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS ACCORDING TO GENDER
6. FEATURES OF FORMATION AND TARGET-DIFFERENTIATED PSYCHOCORRECTION OF PSYCHOLOGICAL MALADAPTATION IN WOMEN WITH NON-CANCER THYROID DISEASE
7. WAIST-TO-HIP RATIO AS A REPRESENTATIVE INDICATOR FOR PRIMARY DETERMINATION OF RISK GROUP FOR NON-ALCOHOLIC FATTY LIVER DISEASE WOMEN WITH TYPE 2 DIABETES MELLITUS
8. Circulating levels of tumor necrosis factor-alpha in type 2 diabetes mellitus patients with non-alcoholic fatty liver disease taking into account the vascular complications
9. Stress and reproductive disorders: modern views on the problem and own research experience
10. Metabolic disorders in patients with excessive weights: formation and forecasting
11. NEW POSSIBILITIES OF TREATMENT OF SUBCLINICAL TIEROTOXICOSIS IN SENIOR PATIENTS: PLACE AND ROLE OF PHYTOTHERAPY
12. CLINICAL AND PATHOGENETIC ASPECTS OF THE PURINE METABOLISM STATE IN DIABETES MELLITUS (review of literature and own observations)
13. STATE CELLULAR IMMUNITY IN PATIENTS WITH DIABETES MELLITUS DEPENDING ON THE BALANCE OF URIC ACID
14. PROPERTIES AND PROSPECTS OF STEM CELL APPLICATION (review and own data)
15. FEATURES OF BONE MINERAL DENSITY IN PATIENTS WITH TYPE 2 DIABETES IN COMBINATION WITH NON-ALCOHOLIC FATTY LIVER DISEASE
16. THE PLACE OF PHYTOTHERAPY IN COMPLEX TREATMENT OF AUTOIMMUNE DISEASES OF THE THYROID GLAND
17. METABOLIC DISBALANCE IN TYPE 2 DIABETES MELLITUS PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE TAKING INTO ACCOUNT THE SINGLE NUCLEOTIDE POLYMORPHISM – 308 G/A OF TUMOR NECROSIS FACTOR-ALPHA (TNF) GENE
18. PATHOGENIC THERAPY OF DIABETIC CYSTOPATHY WITH ALPHA LIPOIC ACID AND GROUP B VITAMINS IN TYPES 1 AND 2 DIABETES MELLITUS PATIENTS
19. DIAGNOSIS AND COURSE OF OSTEOPOROSIS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (literature review and own data)
20. RELATIONSHIP WITH EXPRESSIVENESS OF ALEXITHYMIA WITH PARAMETERS OF CARBOHYDRATE METABOLISM IN PATIENTS WITH TYPE 2 DIABETES IN NONALCOHOLIC FATTY LIVER DISEASE AND OBESITY (Literature review and own data)
21. ALBUMINURIA AS A MARKER OF ENDOTHELIAL DYSFUNCTION AND EARLY PREDICTOR OF CARDIOVASCULAR COMPLICATION IN PATIENTS WITH DIABETES MELLITUS
22. CASE OF PAROXYSMAL HYPERTENSION IN PATIENTS WITH HYPOTHYROIDISM
23. CLINICAL CASE OF LAWRENCE LIPOATROPHIC DIABETES
24. EVIDENCE BASE OF SITAGLIPTIN CLINICAL USE. 10 YEARS IN THE MARKET OF THE WORLD
25. CLINICAL DIAGNOSIS OF URINATION DISORDERS IN PATIENTS WITH DIABETES MELLITUS
26. SINGLE NUCLEOTIDE POLYMORPHISM –308 G/A OF TUMOR NECROSIS FACTOR-ALPHA (TNF) GENE IN TYPE 2 DIABETES MELLITUS PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASESE
27. PANCREATIC AND EXTRA PANCREATIC EFFECTS OF GLYMEPIRIDE
28. ASSESSING THE RISK OF NON-ALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS BY THE COMBINED PATTERN OF RETINOLBINDING PROTEIN-4, HIGH MOLECULAR WEIGHT ADIPONECTIN AND BODY MASS INDEX
29. PRINCIPLES OF EVIDENCE MEDICINE IN COMPLEX THERAPY FOR DIABETIC POLYNEUROPATHY
30. ASSESSING THE RISK OF NONALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
31. RELATIONSHIP ADIPOCYTOKINES WITH ACTIVITY IMMUNE SYSTEM IN TYPE 2 DIABETES MELLITUS COMBINED WITH NONALCOHOLIC FATTY LIVER DISEASE (literature review and own data)
32. DIFFERENCE IN BODY WEIGHT OF PERSONS WITH ENDOCRINE PATHOLOGY — PATIENTS OF ADVISORY POLYCLINIC INSTITUTIONS
33. FIXED COMBINATION OF ANTIDIABETIC DRUGS IN THE TREATMENT OF TYPE 2 DIABETES: FROM THEORY TO PRACTIC
34. TO THE ISSUE OF THE ABDOMINAL OBESITY SPREAD
35. SINGLE NUCLEOTIDE POLYMORPHISM –11391 G>A OF ADIPONECTIN GENE (ADIPOQ) IN TYPE 2 DIABETES PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE
36. CICULATORY LEVELS OF RETINOL-BINDING PROTEIN 4 IN PATIENTS WITH TYPE 2 DIABETES, COMPLICATED BY NON-ALCOHOLIC FATTY LIVER DISEASE
37. CONCERNING OF ACHIEVEMENT COMPENSATION OF TYPE 2 DIABETES MELLITUS
38. THE PROPERTIES OF 8-ISOPROSTAGLANDIN AND ITS RELATIONSHIP WITH OXIDATIVE STRESS IN PATIENTS WITH TYPE 2 DIABETES AND NON-ALCOHOLIC FATTY LIVER DISEASE (review and own research)
39. STRUCTURE OF THE DIFFERENCE IN BODY WEIGHT OF CERTAIN CATEGORIES OF URBAN POPULATION
40. COMBINED THERAPY OF TYPE 2 DIABETES IN THE FAMILY DOCTOR’S PRACTICE
41. THEORETICAL AND PRACTICAL ASPECTS OF GLIMEPYRIDE FEATURES (LITERATURE REVIEW)
42. ETIOTROPIC THERAPY OF FUNGAL INFECTIONS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
43. PRIMARU HYPERALDOSTERONISM
44. THE CONTRIBUTION OF INDIVIDUAL FACTORS IN THE DEVELOPMENT OF TYPE 2 DIABETES IN THE FORMATION OF THE OVERALL HIGH RISK OF DISEASE IN COHORTS OF URBAN AND RURAL POPULATION
45. DIABETES MEDICAL AID STANDARDS (based on «Standards of Medical Care in Diabetes», Diabetes Care 2013;36 Suppl 1:11-66)
46. INTEGRAL INDEX OF THE RISK OF TYPE 2 DIABETES MELLITUS DEVELOPMENT IN A COHORT OF URBAN AND RURAL HABITANTS
47. TYPE 2 DIABETES, NON-ALCOHOLIC FATTY LIVER DISEASE AND OXIDATIVE STRESS. THERAPEUTIC APPROACHES (LITERATURE REVIEW AND OWN DATA)
48. REMOTE RESULTS OF USING THREE-HYPOGLYCEMIC THERAPY IN PATIENTS WITH TYPE 2 DIABETES
49. MODERN DIAGNOSTICAL MARKERS OF DIABETICAL NEUROPATHY
50. UROGENITAL FORM OF DIABETIC AUTONOMOUS NEUROPATHIES: PREVALENCE, ETIOPATHOGENESIS, DIAGNOSTICS
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.